Compare TYRA & FIGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | FIGS |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2021 | 2021 |
| Metric | TYRA | FIGS |
|---|---|---|
| Price | $32.81 | $10.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $47.50 | $15.93 |
| AVG Volume (30 Days) | 988.1K | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 850.00 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $419,591,000.00 |
| Revenue This Year | N/A | $14.09 |
| Revenue Next Year | N/A | $7.72 |
| P/E Ratio | ★ N/A | $344.33 |
| Revenue Growth | N/A | ★ 59.47 |
| 52 Week Low | $9.96 | $5.97 |
| 52 Week High | $40.65 | $17.48 |
| Indicator | TYRA | FIGS |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 37.98 |
| Support Level | $29.68 | $9.92 |
| Resistance Level | $33.99 | $10.24 |
| Average True Range (ATR) | 1.84 | 0.61 |
| MACD | 0.47 | -0.04 |
| Stochastic Oscillator | 93.67 | 18.18 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
FIGS Inc is a healthcare apparel company. It designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other healthcare apparel. The company sells products mainly through its direct-to-consumer (DTC) digital platform, consisting of its website, mobile app, and B2B business (TEAMS). It also operates physical retail stores, which are called Community Hubs, providing a retail experience for healthcare professionals. The company generates maximum revenue from the sale of scrubwear products. Geographically, it derives maximum revenue from the United States, followed by the rest of the world.